Alan Thomas
LightNews LightNews
alanthomas.bsky.social
Alan Thomas
@alanthomas.bsky.social
59 followers 82 following 36 posts
Posts Replies Media Videos
alanthomas.bsky.social
IMO, that would be a net positive benefit for the UK.
December 5, 2025 at 10:30 AM
Reposted by Alan Thomas
sailorrooscout.bsky.social
Current treatments require repeated injections directly into the eye, but this vaccine can be delivered intramuscularly, making it less invasive and easier to administer.

The study has been published in Vaccine. YES, it is PEER-REVIEWED.
• www.sciencedirect.com/science/arti...

🧪🧵⬇️
Summary A new mRNA vaccine developed in Japan has been shown to suppress abnormal blood vessel growth in the retina of mice, offering hope for patients with age-related macular degeneration (AMD). Current treatments require repeated injections directly into the eye, but this vaccine can be delivered intramuscularly, making it less invasive and easier to administer. By targeting LRG1, a protein linked to abnormal angiogenesis, the vaccine triggered strong antibody responses that reduced retinal damage by up to 85% in mouse models. If successful in humans, this approach could transform AMD treatment and significantly reduce the burden of eye injections. Key Facts Mechanism The vaccine blocks LRG1, a protein promoting abnormal blood vessel growth. Effectiveness Reduced retinal leakage by 85% and lesion size by 82% in mouse models. Advantage Works as well as anti-VEGF therapy but requires only a simple arm injection. Source Institute of Science Tokyo
November 2, 2025 at 5:02 PM